Atrys Health (XMAD:ATRY) Cash Flow from Others: €29.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ATRY Atrys Health SA XMAD:ATRY
68 GF Score
Price €2.78
GF Value €3.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Atrys Health Cash Flow from Others?

Atrys Health XMAD:ATRY +2.78% 68 Cash Flow from Others is €29.4 Mil as of Jun. 2026. GuruFocus rates XMAD:ATRY with a GF Score™ of 68/100 and a GF Value™ of €3.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Atrys Health's cash flow from others for the six months ended in Jun. 2026 was €2.6 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2026 was €29.4 Mil.

Atrys Health Cash Flow from Others Related Terms

Atrys Health Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Atrys Health's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health Cash Flow from Others Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.77 -0.87 10.84 14.06 27.66

Atrys Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 13.18 0.89 26.77 2.65
XMAD:ATRY
68GF Score
Atrys Health SA XMAD:ATRY
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €29.4 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of €29.4 Mil mean?
Atrys Health (XMAD:ATRY) has a Cash Flow from Others of €29.4 Mil as of Jun. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Atrys Health and its competitors.
Is Atrys Health's Cash Flow from Others too high?
Atrys Health's current Cash Flow from Others is €29.4 Mil. Overall, Atrys Health has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Cash Flow from Others compare to VRTX and REGN?
Atrys Health's Cash Flow from Others of €29.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Atrys Health and its competitors. Atrys Health's current Cash Flow from Others is €29.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.19, compared to a current price of €2.78 — trading 13% below its estimated fair value. The current Cash Flow from Others is €29.4 Mil. Atrys Health's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Cash Flow from Others is €29.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.78 is trading 13% below its estimated GF Value™ of €3.19. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Cash Flow from Others: €29.4 Mil
  • GF Value™: €3.19 vs. price of €2.78 (13% below fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score

Get the complete analysis for XMAD:ATRY

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price
€3.19
GF Value